한국지질동맥경화학회 학술대회

This session, "Genetic Insights into Dyslipidemia and Diabetes: Pathways, Predictions, and Interventions," delves into the latest genetic advances impacting cardiovascular and metabolic diseases. Attendees will explore the evolving genetic landscape of cardiovascular disease (CVD) and diabetes, considering future implications for prediction and prevention. The second presentation examines the powers of multi-omics and multi-trait analyses in unraveling the complexity of metabolic disorders. Next, exciting developments in gene therapy for familial hypercholesterolemia will be showcased, highlighting cutting-edge interventions. The session concludes with an engaging discussion, fostering collaboration and reflection on how genetic research can translate into better clinical outcomes.

This session entitled “Emerging Drugs for Dyslipidemia Management” addresses innovative pharmacological strategies to tackle residual lipid risk that persists despite statin therapy. While LDL-C reduction remains the cornerstone of dyslipidemia management, a substantial number of patients continue to face elevated cardiovascular risk due to hypertriglyceridemia, elevated remnant cholesterol, or persistent atherogenic dyslipidemia. The first lecture will examine the real-world clinical applications of bempedoic acid and identify patient populations who may derive maximum therapeutic benefit. The second lecture will focus on APOC3 inhibition strategies for severe hypertriglyceridemia management, discussing clinical applicability in familial chylomicronemia syndrome and mixed dyslipidemia with supporting evidence from recent clinical trials. The final lecture will present the regulatory mechanisms of ANGPTL3 and ANGPTL8 in lipid metabolism and introduce the development status of next-generation therapeutic approaches targeting these pathways. Through this session, attendees will gain comprehensive insights into the latest paradigms in lipid-lowering therapy and future prospects for clinical implementation.